X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) Stock Competitors & Peer Comparison
See XFOR's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for XFOR and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| XFOR | $3.94 | +2.34% | 371.6M | -0.87 | -$4.54 | N/A |
| VRTX | $479.00 | +0.34% | 121.6B | 25.45 | $18.82 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $667.17 | +1.70% | 68.7B | 14.62 | $45.63 | +0.54% |
| ARGX | $888.82 | -3.20% | 55.3B | 80.22 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $188.07 | -0.61% | 40B | -26.60 | -$7.07 | N/A |
| RVMDW | $9.55 | +0.53% | 39.8B | -2.27 | -$4.15 | N/A |
| ALNY | $278.40 | +2.44% | 37.2B | 50.16 | $5.55 | N/A |
| ONC | $325.90 | +0.00% | 34.8B | 72.91 | $4.47 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
XFOR vs VRTX Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, VRTX has a market cap of 121.6B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while VRTX trades at $479.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas VRTX's P/E ratio is 25.45. In terms of profitability, XFOR's ROE is -0.95%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, XFOR is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check VRTX's competition here
Verona Pharma plc (NASDAQ: VRNA)
XFOR vs VRNA Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas VRNA's P/E ratio is -102.80. In terms of profitability, XFOR's ROE is -0.95%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, XFOR is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check VRNA's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
XFOR vs REGN Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, REGN has a market cap of 68.7B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while REGN trades at $667.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas REGN's P/E ratio is 14.62. In terms of profitability, XFOR's ROE is -0.95%, compared to REGN's ROE of +0.14%. Regarding short-term risk, XFOR is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check REGN's competition here
argenx SE (NASDAQ: ARGX)
XFOR vs ARGX Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, ARGX has a market cap of 55.3B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while ARGX trades at $888.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas ARGX's P/E ratio is 80.22. In terms of profitability, XFOR's ROE is -0.95%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, XFOR is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
XFOR vs SGEN Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas SGEN's P/E ratio is -57.19. In terms of profitability, XFOR's ROE is -0.95%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, XFOR is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
XFOR vs RVMD Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, RVMD has a market cap of 40B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while RVMD trades at $188.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas RVMD's P/E ratio is -26.60. In terms of profitability, XFOR's ROE is -0.95%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, XFOR is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check RVMD's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
XFOR vs RVMDW Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, RVMDW has a market cap of 39.8B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while RVMDW trades at $9.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas RVMDW's P/E ratio is -2.27. In terms of profitability, XFOR's ROE is -0.95%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, XFOR is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for XFOR.Check RVMDW's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
XFOR vs ALNY Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, ALNY has a market cap of 37.2B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while ALNY trades at $278.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas ALNY's P/E ratio is 50.16. In terms of profitability, XFOR's ROE is -0.95%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, XFOR is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check ALNY's competition here
BeOne Medicines AG (NASDAQ: ONC)
XFOR vs ONC Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, ONC has a market cap of 34.8B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while ONC trades at $325.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas ONC's P/E ratio is 72.91. In terms of profitability, XFOR's ROE is -0.95%, compared to ONC's ROE of +0.12%. Regarding short-term risk, XFOR is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check ONC's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
XFOR vs ROIV Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, ROIV has a market cap of 25B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while ROIV trades at $34.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas ROIV's P/E ratio is -35.69. In terms of profitability, XFOR's ROE is -0.95%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, XFOR is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
XFOR vs INCY Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, INCY has a market cap of 23.7B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while INCY trades at $118.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas INCY's P/E ratio is 15.98. In terms of profitability, XFOR's ROE is -0.95%, compared to INCY's ROE of +0.29%. Regarding short-term risk, XFOR is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
XFOR vs BNTX Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, BNTX has a market cap of 23B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while BNTX trades at $91.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas BNTX's P/E ratio is -19.72. In terms of profitability, XFOR's ROE is -0.95%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, XFOR is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check BNTX's competition here
Insmed Incorporated (NASDAQ: INSM)
XFOR vs INSM Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, INSM has a market cap of 22.7B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while INSM trades at $104.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas INSM's P/E ratio is -18.21. In terms of profitability, XFOR's ROE is -0.95%, compared to INSM's ROE of -1.30%. Regarding short-term risk, XFOR is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check INSM's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
XFOR vs UTHR Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, UTHR has a market cap of 22.4B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while UTHR trades at $527.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas UTHR's P/E ratio is 19.49. In terms of profitability, XFOR's ROE is -0.95%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, XFOR is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check UTHR's competition here
Moderna, Inc. (NASDAQ: MRNA)
XFOR vs MRNA Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, MRNA has a market cap of 22.1B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while MRNA trades at $55.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas MRNA's P/E ratio is -6.83. In terms of profitability, XFOR's ROE is -0.95%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, XFOR is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for XFOR.Check MRNA's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
XFOR vs BGNE Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas BGNE's P/E ratio is -22.55. In terms of profitability, XFOR's ROE is -0.95%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, XFOR is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
XFOR vs DNA-WT Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, XFOR's ROE is -0.95%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, XFOR is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for XFOR.Check DNA-WT's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
XFOR vs NBIX Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, NBIX has a market cap of 17.7B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while NBIX trades at $176.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas NBIX's P/E ratio is 25.49. In terms of profitability, XFOR's ROE is -0.95%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, XFOR is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check NBIX's competition here
Genmab A/S (NASDAQ: GMAB)
XFOR vs GMAB Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, GMAB has a market cap of 17.7B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while GMAB trades at $28.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas GMAB's P/E ratio is 20.72. In terms of profitability, XFOR's ROE is -0.95%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, XFOR is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check GMAB's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
XFOR vs BBIO Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, BBIO has a market cap of 16.5B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while BBIO trades at $84.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas BBIO's P/E ratio is -22.49. In terms of profitability, XFOR's ROE is -0.95%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, XFOR is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check BBIO's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
XFOR vs JAZZ Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, JAZZ has a market cap of 16B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while JAZZ trades at $255.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas JAZZ's P/E ratio is 19.86. In terms of profitability, XFOR's ROE is -0.95%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, XFOR is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check JAZZ's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
XFOR vs ASND Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, ASND has a market cap of 15.7B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while ASND trades at $253.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas ASND's P/E ratio is -104.72. In terms of profitability, XFOR's ROE is -0.95%, compared to ASND's ROE of -56.42%. Regarding short-term risk, XFOR is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
XFOR vs EXEL Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, EXEL has a market cap of 14B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while EXEL trades at $55.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas EXEL's P/E ratio is 16.71. In terms of profitability, XFOR's ROE is -0.95%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, XFOR is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check EXEL's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
XFOR vs MDGL Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, MDGL has a market cap of 12.7B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while MDGL trades at $551.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas MDGL's P/E ratio is -43.07. In terms of profitability, XFOR's ROE is -0.95%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, XFOR is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check MDGL's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
XFOR vs KRTX Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas KRTX's P/E ratio is -28.09. In terms of profitability, XFOR's ROE is -0.95%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, XFOR is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check KRTX's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
XFOR vs AXSM Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, AXSM has a market cap of 12.3B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while AXSM trades at $238.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas AXSM's P/E ratio is -62.24. In terms of profitability, XFOR's ROE is -0.95%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, XFOR is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check AXSM's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
XFOR vs ARWR Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, ARWR has a market cap of 12B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while ARWR trades at $85.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas ARWR's P/E ratio is -39.78. In terms of profitability, XFOR's ROE is -0.95%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, XFOR is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check ARWR's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
XFOR vs BMRN Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while BMRN trades at $60.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas BMRN's P/E ratio is 28.98. In terms of profitability, XFOR's ROE is -0.95%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, XFOR is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check BMRN's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
XFOR vs RNAM Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas RNAM's P/E ratio is -17.39. In terms of profitability, XFOR's ROE is -0.95%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, XFOR is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check RNAM's competition here
Bio-Techne Corporation (NASDAQ: TECH)
XFOR vs TECH Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, TECH has a market cap of 11.2B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while TECH trades at $71.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas TECH's P/E ratio is 36.91. In terms of profitability, XFOR's ROE is -0.95%, compared to TECH's ROE of +0.05%. Regarding short-term risk, XFOR is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check TECH's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
XFOR vs KRYS Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, KRYS has a market cap of 10.4B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while KRYS trades at $351.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas KRYS's P/E ratio is 47.03. In terms of profitability, XFOR's ROE is -0.95%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, XFOR is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for XFOR.Check KRYS's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
XFOR vs SMMT Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, SMMT has a market cap of 10.2B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while SMMT trades at $13.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas SMMT's P/E ratio is -8.19. In terms of profitability, XFOR's ROE is -0.95%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, XFOR is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for XFOR.Check SMMT's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
XFOR vs CYTK Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, CYTK has a market cap of 10B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while CYTK trades at $80.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas CYTK's P/E ratio is -13.83. In terms of profitability, XFOR's ROE is -0.95%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, XFOR is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check CYTK's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
XFOR vs HALO Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, HALO has a market cap of 9.7B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while HALO trades at $81.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas HALO's P/E ratio is 17.64. In terms of profitability, XFOR's ROE is -0.95%, compared to HALO's ROE of +1.26%. Regarding short-term risk, XFOR is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check HALO's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
XFOR vs RXDX Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas RXDX's P/E ratio is -56.47. In terms of profitability, XFOR's ROE is -0.95%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, XFOR is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check RXDX's competition here
Abivax S.A. (NASDAQ: ABVX)
XFOR vs ABVX Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, ABVX has a market cap of 9.4B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while ABVX trades at $128.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas ABVX's P/E ratio is -67.09. In terms of profitability, XFOR's ROE is -0.95%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, XFOR is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for XFOR.Check ABVX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
XFOR vs IONS Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, IONS has a market cap of 9.2B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while IONS trades at $55.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas IONS's P/E ratio is -32.53. In terms of profitability, XFOR's ROE is -0.95%, compared to IONS's ROE of -0.59%. Regarding short-term risk, XFOR is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check IONS's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
XFOR vs NUVL Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas NUVL's P/E ratio is -21.79. In terms of profitability, XFOR's ROE is -0.95%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, XFOR is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check NUVL's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
XFOR vs KYMR Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, KYMR has a market cap of 9.1B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while KYMR trades at $110.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas KYMR's P/E ratio is -31.18. In terms of profitability, XFOR's ROE is -0.95%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, XFOR is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check KYMR's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
XFOR vs CRNX Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, CRNX has a market cap of 8.9B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while CRNX trades at $83.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas CRNX's P/E ratio is -16.35. In terms of profitability, XFOR's ROE is -0.95%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, XFOR is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check CRNX's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
XFOR vs PRAX Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, PRAX has a market cap of 8.8B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while PRAX trades at $315.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas PRAX's P/E ratio is -23.62. In terms of profitability, XFOR's ROE is -0.95%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, XFOR is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for XFOR.Check PRAX's competition here
Alkermes plc (NASDAQ: ALKS)
XFOR vs ALKS Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, ALKS has a market cap of 8.8B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while ALKS trades at $52.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas ALKS's P/E ratio is 55.51. In terms of profitability, XFOR's ROE is -0.95%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, XFOR is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check ALKS's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
XFOR vs IMGN Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas IMGN's P/E ratio is -111.55. In terms of profitability, XFOR's ROE is -0.95%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, XFOR is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check IMGN's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
XFOR vs PTGX Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, PTGX has a market cap of 8.7B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while PTGX trades at $135.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas PTGX's P/E ratio is -74.90. In terms of profitability, XFOR's ROE is -0.95%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, XFOR is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check PTGX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
XFOR vs SYRE Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, SYRE has a market cap of 8.7B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while SYRE trades at $100.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas SYRE's P/E ratio is -48.10. In terms of profitability, XFOR's ROE is -0.95%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, XFOR is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for XFOR.Check SYRE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
XFOR vs TGTX Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, TGTX has a market cap of 8.5B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while TGTX trades at $55.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas TGTX's P/E ratio is 19.16. In terms of profitability, XFOR's ROE is -0.95%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, XFOR is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check TGTX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
XFOR vs BPMC Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas BPMC's P/E ratio is -51.58. In terms of profitability, XFOR's ROE is -0.95%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, XFOR is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
XFOR vs APGE Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while APGE trades at $134.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas APGE's P/E ratio is -31.01. In terms of profitability, XFOR's ROE is -0.95%, compared to APGE's ROE of -0.33%. Regarding short-term risk, XFOR is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check APGE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
XFOR vs IMVT Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, IMVT has a market cap of 8.2B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while IMVT trades at $40.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas IMVT's P/E ratio is -15.01. In terms of profitability, XFOR's ROE is -0.95%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, XFOR is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check IMVT's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
XFOR vs CERE Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas CERE's P/E ratio is -16.47. In terms of profitability, XFOR's ROE is -0.95%, compared to CERE's ROE of -0.72%. Regarding short-term risk, XFOR is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check CERE's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
XFOR vs PCVX Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, PCVX has a market cap of 8B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while PCVX trades at $55.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas PCVX's P/E ratio is -8.07. In terms of profitability, XFOR's ROE is -0.95%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, XFOR is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check PCVX's competition here
Metsera, Inc. (NASDAQ: MTSR)
XFOR vs MTSR Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas MTSR's P/E ratio is -23.58. In terms of profitability, XFOR's ROE is -0.95%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, XFOR is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check MTSR's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
XFOR vs IBRX Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, IBRX has a market cap of 7.3B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while IBRX trades at $6.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas IBRX's P/E ratio is -8.22. In terms of profitability, XFOR's ROE is -0.95%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, XFOR is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for XFOR.Check IBRX's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
XFOR vs RYTM Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, RYTM has a market cap of 7.3B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while RYTM trades at $106.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas RYTM's P/E ratio is -33.91. In terms of profitability, XFOR's ROE is -0.95%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, XFOR is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for XFOR.Check RYTM's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
XFOR vs MIRM Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, MIRM has a market cap of 7B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while MIRM trades at $114.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas MIRM's P/E ratio is -8.39. In terms of profitability, XFOR's ROE is -0.95%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, XFOR is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check MIRM's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
XFOR vs COGT Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, COGT has a market cap of 6.9B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while COGT trades at $40.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas COGT's P/E ratio is -19.17. In terms of profitability, XFOR's ROE is -0.95%, compared to COGT's ROE of -0.83%. Regarding short-term risk, XFOR is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check COGT's competition here
Merus N.V. (NASDAQ: MRUS)
XFOR vs MRUS Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas MRUS's P/E ratio is -17.05. In terms of profitability, XFOR's ROE is -0.95%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, XFOR is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
XFOR vs ACLX Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas ACLX's P/E ratio is -28.27. In terms of profitability, XFOR's ROE is -0.95%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, XFOR is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
XFOR vs RETA Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas RETA's P/E ratio is -66.29. In terms of profitability, XFOR's ROE is -0.95%, compared to RETA's ROE of +0.47%. Regarding short-term risk, XFOR is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check RETA's competition here
Erasca, Inc. (NASDAQ: ERAS)
XFOR vs ERAS Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, ERAS has a market cap of 6.6B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while ERAS trades at $18.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas ERAS's P/E ratio is -20.29. In terms of profitability, XFOR's ROE is -0.95%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, XFOR is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for XFOR.Check ERAS's competition here
CG Oncology Inc. (NASDAQ: CGON)
XFOR vs CGON Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, CGON has a market cap of 6.5B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while CGON trades at $73.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas CGON's P/E ratio is -31.55. In terms of profitability, XFOR's ROE is -0.95%, compared to CGON's ROE of -0.23%. Regarding short-term risk, XFOR is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for XFOR.Check CGON's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
XFOR vs XENE Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, XENE has a market cap of 6.4B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while XENE trades at $65.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas XENE's P/E ratio is -14.00. In terms of profitability, XFOR's ROE is -0.95%, compared to XENE's ROE of -0.49%. Regarding short-term risk, XFOR is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check XENE's competition here
Belite Bio, Inc (NASDAQ: BLTE)
XFOR vs BLTE Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while BLTE trades at $158.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas BLTE's P/E ratio is -84.72. In terms of profitability, XFOR's ROE is -0.95%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, XFOR is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check BLTE's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
XFOR vs PTCT Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, PTCT has a market cap of 6.3B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while PTCT trades at $75.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas PTCT's P/E ratio is -32.53. In terms of profitability, XFOR's ROE is -0.95%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, XFOR is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for XFOR.Check PTCT's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
XFOR vs CNTA Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas CNTA's P/E ratio is -22.63. In terms of profitability, XFOR's ROE is -0.95%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, XFOR is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check CNTA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
XFOR vs LGND Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, LGND has a market cap of 6B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while LGND trades at $297.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas LGND's P/E ratio is 35.67. In terms of profitability, XFOR's ROE is -0.95%, compared to LGND's ROE of +0.16%. Regarding short-term risk, XFOR is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check LGND's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
XFOR vs SRRK Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, SRRK has a market cap of 5.9B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while SRRK trades at $48.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas SRRK's P/E ratio is -13.63. In terms of profitability, XFOR's ROE is -0.95%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, XFOR is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check SRRK's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
XFOR vs CDTX Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas CDTX's P/E ratio is -19.77. In terms of profitability, XFOR's ROE is -0.95%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, XFOR is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
XFOR vs ABCM Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, XFOR's ROE is -0.95%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, XFOR is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
XFOR vs ISEE Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas ISEE's P/E ratio is -22.44. In terms of profitability, XFOR's ROE is -0.95%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, XFOR is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check ISEE's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
XFOR vs TVTX Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, TVTX has a market cap of 5.3B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while TVTX trades at $56.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas TVTX's P/E ratio is -257.64. In terms of profitability, XFOR's ROE is -0.95%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, XFOR is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check TVTX's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
XFOR vs APLS Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas APLS's P/E ratio is 38.35. In terms of profitability, XFOR's ROE is -0.95%, compared to APLS's ROE of +0.40%. Regarding short-term risk, XFOR is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check APLS's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
XFOR vs TERN Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas TERN's P/E ratio is -51.41. In terms of profitability, XFOR's ROE is -0.95%, compared to TERN's ROE of -0.20%. Regarding short-term risk, XFOR is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check TERN's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
XFOR vs DFTX Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while DFTX trades at $42.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas DFTX's P/E ratio is N/A. In terms of profitability, XFOR's ROE is -0.95%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, XFOR is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for XFOR.Check DFTX's competition here
Veradermics, Incorporated (NYSE: MANE)
XFOR vs MANE Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, MANE has a market cap of 4.7B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while MANE trades at $111.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas MANE's P/E ratio is -35.45. In terms of profitability, XFOR's ROE is -0.95%, compared to MANE's ROE of -0.84%. Regarding short-term risk, XFOR is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for XFOR.Check MANE's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
XFOR vs FOLD Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas FOLD's P/E ratio is -161.00. In terms of profitability, XFOR's ROE is -0.95%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, XFOR is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check FOLD's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
XFOR vs CRSP Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, CRSP has a market cap of 4.5B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while CRSP trades at $46.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas CRSP's P/E ratio is -9.15. In terms of profitability, XFOR's ROE is -0.95%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, XFOR is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check CRSP's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
XFOR vs AKRO Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas AKRO's P/E ratio is -14.57. In terms of profitability, XFOR's ROE is -0.95%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, XFOR is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check AKRO's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
XFOR vs EWTX Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, EWTX has a market cap of 4.5B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while EWTX trades at $41.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas EWTX's P/E ratio is -25.06. In terms of profitability, XFOR's ROE is -0.95%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, XFOR is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check EWTX's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
XFOR vs ALPN Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas ALPN's P/E ratio is -101.52. In terms of profitability, XFOR's ROE is -0.95%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, XFOR is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check ALPN's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
XFOR vs CAI Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while CAI trades at $15.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas CAI's P/E ratio is -85.97. In terms of profitability, XFOR's ROE is -0.95%, compared to CAI's ROE of +0.06%. Regarding short-term risk, XFOR is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check CAI's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
XFOR vs DNTH Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, DNTH has a market cap of 4.4B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while DNTH trades at $104.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas DNTH's P/E ratio is -25.30. In terms of profitability, XFOR's ROE is -0.95%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, XFOR is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check DNTH's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
XFOR vs ACAD Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, ACAD has a market cap of 4.3B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while ACAD trades at $25.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas ACAD's P/E ratio is 12.45. In terms of profitability, XFOR's ROE is -0.95%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, XFOR is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check ACAD's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
XFOR vs DYN Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, DYN has a market cap of 4.2B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while DYN trades at $25.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas DYN's P/E ratio is -7.96. In terms of profitability, XFOR's ROE is -0.95%, compared to DYN's ROE of -0.58%. Regarding short-term risk, XFOR is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for XFOR.Check DYN's competition here
Opthea Limited (NASDAQ: OPT)
XFOR vs OPT Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas OPT's P/E ratio is -1.52. In terms of profitability, XFOR's ROE is -0.95%, compared to OPT's ROE of +1.18%. Regarding short-term risk, XFOR is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check OPT's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
XFOR vs MRTX Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas MRTX's P/E ratio is -4.82. In terms of profitability, XFOR's ROE is -0.95%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, XFOR is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check MRTX's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
XFOR vs VKTX Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, VKTX has a market cap of 4B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while VKTX trades at $34.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas VKTX's P/E ratio is -8.42. In terms of profitability, XFOR's ROE is -0.95%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, XFOR is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check VKTX's competition here
Celcuity Inc. (NASDAQ: CELC)
XFOR vs CELC Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, CELC has a market cap of 4B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while CELC trades at $82.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas CELC's P/E ratio is -21.09. In terms of profitability, XFOR's ROE is -0.95%, compared to CELC's ROE of -2.45%. Regarding short-term risk, XFOR is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for XFOR.Check CELC's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
XFOR vs CPRX Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas CPRX's P/E ratio is 12.30. In terms of profitability, XFOR's ROE is -0.95%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, XFOR is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check CPRX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
XFOR vs ELVN Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, ELVN has a market cap of 3.8B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while ELVN trades at $52.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas ELVN's P/E ratio is -31.58. In terms of profitability, XFOR's ROE is -0.95%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, XFOR is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for XFOR.Check ELVN's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
XFOR vs RYZB Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas RYZB's P/E ratio is -57.86. In terms of profitability, XFOR's ROE is -0.95%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, XFOR is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check RYZB's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
XFOR vs DNLI Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while DNLI trades at $23.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas DNLI's P/E ratio is -8.18. In terms of profitability, XFOR's ROE is -0.95%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, XFOR is more volatile compared to DNLI. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check DNLI's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
XFOR vs CBAY Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas CBAY's P/E ratio is -32.81. In terms of profitability, XFOR's ROE is -0.95%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, XFOR is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check CBAY's competition here
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMSW)
XFOR vs NAMSW Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, NAMSW has a market cap of 3.6B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while NAMSW trades at $19.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas NAMSW's P/E ratio is -10.75. In terms of profitability, XFOR's ROE is -0.95%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, XFOR is more volatile compared to NAMSW. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check NAMSW's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
XFOR vs ADPT Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, ADPT has a market cap of 3.6B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while ADPT trades at $22.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas ADPT's P/E ratio is -41.74. In terms of profitability, XFOR's ROE is -0.95%, compared to ADPT's ROE of -0.24%. Regarding short-term risk, XFOR is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for XFOR.Check ADPT's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
XFOR vs LEGN Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, LEGN has a market cap of 3.6B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while LEGN trades at $19.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas LEGN's P/E ratio is -28.34. In terms of profitability, XFOR's ROE is -0.95%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, XFOR is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for XFOR.Check LEGN's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
XFOR vs SWTX Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas SWTX's P/E ratio is -13.78. In terms of profitability, XFOR's ROE is -0.95%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, XFOR is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check SWTX's competition here
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS)
XFOR vs NAMS Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, NAMS has a market cap of 3.5B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while NAMS trades at $30.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas NAMS's P/E ratio is -19.01. In terms of profitability, XFOR's ROE is -0.95%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, XFOR is more volatile compared to NAMS. This indicates higher risk in terms of short-term price fluctuations for XFOR.Check NAMS's competition here
Arcus Biosciences, Inc. (NYSE: RCUS)
XFOR vs RCUS Comparison July 2026
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XFOR stands at 371.6M. In comparison, RCUS has a market cap of 3.5B. Regarding current trading prices, XFOR is priced at $3.94 on the NASDAQ, while RCUS trades at $27.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XFOR currently has a P/E ratio of -0.87, whereas RCUS's P/E ratio is -8.56. In terms of profitability, XFOR's ROE is -0.95%, compared to RCUS's ROE of -0.69%. Regarding short-term risk, XFOR is less volatile compared to RCUS. This indicates lower risk in terms of short-term price fluctuations for XFOR.Check RCUS's competition here